Marcel Nijland
dr.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
Serum TARC: a biomarker for early detection or exclusion of relapse in classic Hodgkin Lymphoma
Published in: Blood Advances
Access to document
10.1182/bloodadvances.2025015837
document
Atezolizumab Consolidation in Patients with High Risk Diffuse Large B-cell Lymphoma in Complete Remission after R-CHOP
Published in: Blood Advances
Access to document
10.1182/bloodadvances.2024015226
document
The risk of relapse among high-risk diffuse large B-cell lymphoma (DLBCL) patients in complete metabolic remission (CMR) following R-CHOP therapy is 20-25%. Here, we evaluated whether consolidation with the PDL-1 checkpoint inhibitor atezolizumab could reduce the relapse risk. In this phase II, open-label trial (NCT03463057) DLBCL patients with an international prognostic index (IPI) score of ≥ 3 and CMR after R-CHOP received 1200mg atezolizumab every 3 weeks for 18 cycles. The primary endpoint was disease-free survival (DFS) at 2 years with the aim of improving it to 89%...
Marcel Nijland, Djamila E Issa, Johanna A A Bult, Dries Deeren, Gerjo A Velders, Marten R Nijziel, Yorick Sandberg, Vibeke Kj Vergote, Margriet Oosterveld, Rob Fijnheer, Rolf Brouwer, Rinske Boersma, Kalung Wu, Laurens Nieuwenhuizen, Joost Sp Vermaat, Roel J W van Kampen, Wim E Terpstra, Sylvia Snauwaert, Marjolein Wm van der Poel, Eva de JonghMarc Durian, Leonie Strobbe, Aart Beeker, Alain Pa Gadisseur, Roos Van Rijn, Otto J Visser, Jeanette Doorduijn, Tjeerd J F Snijders, Matthijs H Silbermann, Daphne de Jong, Martine E D Chamuleau, Rogier Mous, Mathilde Jalving, Heleen Visser-Wisselaar, Sonja Jansen van den Bergh, Gerben Jc Zwezerijnen, Edwin Bremer, Mirian Brink, Arjan Diepstra, Dana A Chitu, Harry R Koene, Josée M Zijlstra
Consolidation With Second High Dose Therapy and Autologous Stem Cell Transplantation Is Associated With Improved Overall Survival in Patients With Multiple Myeloma in First Relapse
Published in: Clinical lymphoma, myeloma & leukemia
Access to document
10.1016/j.clml.2024.12.010
document
BACKGROUND: High dose chemotherapy and autologous stem cell transplantation (HDT/ASCT) remains the preferred first line consolidation strategy for newly diagnosed multiple myeloma (MM). However, The role of HDT/ASCT in first relapse is uncertain in the context of novel therapies. This study evaluates real-world outcomes of MM patients in first relapse, focusing on the role of consolidative HDT/ASCT. PATIENTS AND METHODS: This retrospective cohort study was conducted at a large tertiary referral center in Northern Netherlands. MM patients who received first-line HDT/ASCT and obtained a good response were included....
Koen M Klomberg, Miriam Gelderloos, Hilde A M Kooistra, Marcel Nijland, Gerwin A Huls, Wilfried W H Roeloffzen, Wouter J Plattel
Molecular profiling of cell-free DNA from classic Hodgkin lymphoma patients identifies potential prognostic clusters and corresponds with disease dynamics
Published in: Annals of Hematology
Access to document
10.1007/s00277-025-06328-8
document
Cell-free DNA (cfDNA) analysis has advantages over tissue analysis for molecular profiling of classic Hodgkin lymphoma (cHL) at diagnosis and offers additional opportunities for sensitive non-invasive disease tracking during treatment. The aim of this study is to correlate cfDNA based molecular profiling with disease characteristics including serum Thymus and Activation Regulated Chemokine (TARC) levels and FDG-PET imaging, which are established markers of disease assessment. cfDNA isolated from plasma samples of 42 cHL patients was analyzed using low coverage whole genome and targeted next-generation sequencing. Patients were clustered in...
Nick Veltmaat, Geok-Wee Tan, Yujie Zhong, Sophie Teesink, Martijn Terpstra, Johanna Bult, Marcel Nijland, Joost Kluiver, Arjan Diepstra, Anke van den Berg, Wouter J Plattel
Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma
Published in: Nature Communications
Access to document
10.1038/s41467-024-55614-y
document
Next Generation Sequencing-based subtyping and interim- and end of treatment positron emission tomography (i/eot-PET) monitoring have high potential for upfront and on-treatment risk assessment of diffuse large B-cell lymphoma patients. We performed Dana Farber Cancer Institute (DFCI) and LymphGen genetic subtyping for the HOVON84 (n = 208, EudraCT-2006-005174-42) and PETAL (n = 204, EudraCT-2006-001641-33) trials retrospectively combined with DFCI genetic data (n = 304). For all R-CHOP treated patients (n = 592), C5/MCD- and C2/A53-subtypes show significantly worse outcome independent of the international prognostic index. For all subtypes, adverse prognostic value of i/eot-PET-positive status is confirmed....
Matías S Mendeville, Jurriaan Janssen, G Tjitske Los-de Vries, Erik van Dijk, Julia Richter, Marcel Nijland, Margaretha G M Roemer, Phylicia Stathi, Nathalie J Hijmering, Reno Bladergroen, Diego A Pelaz, Arjan Diepstra, Corinne J Eertink, Coreline N Burggraaff, Yongsoo Kim, Pieternella J Lugtenburg, Anke van den Berg, Alexandar Tzankov, Stefan Dirnhofer, Ulrich DührsenAndreas Hüttmann, Wolfram Klapper, Josée M Zijlstra, Bauke Ylstra, Daphne de Jong